Effectiveness of single-inhaler triple therapy on exacerbation risk and mortality in COPD is exaggerated in IMPACT and ETHOS trials from confounding by prior ICS discontinuation: effectiveness fades in analyses and studies with no prior ICS discontinuation https://bit.ly/3tOgNdW.
Keyphrases
- chronic obstructive pulmonary disease
- randomized controlled trial
- lung function
- systematic review
- cardiovascular events
- electronic health record
- intensive care unit
- stem cells
- cardiovascular disease
- coronary artery disease
- mesenchymal stem cells
- cystic fibrosis
- machine learning
- bone marrow
- extracorporeal membrane oxygenation
- artificial intelligence